Pair Name	Homoharringtonine, ACC010
Partner Name	Homoharringtonine
Disease Info	[ICD-11: 2A60.Z]	Acute myeloid leukemia		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Up-regulation	Cleavage	PARP1	hsa142
	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Cleavage	CASP7	hsa840
	Down-regulation	Phosphorylation	RB1	hsa5925
	Down-regulation	Expression	CDK2	hsa1017
	Down-regulation	Expression	CDK4	hsa1019
	Down-regulation	Expression	CDK6	hsa1021
	Up-regulation	Expression	CDKN1A	hsa1026
	Up-regulation	Expression	PSMD9	hsa5715
	Down-regulation	Phosphorylation	FLT3	hsa2322
	Down-regulation	Phosphorylation	STAT5	hsa6776
	Down-regulation	Phosphorylation	AKT1	hsa207
	Down-regulation	Expression	MYC	hsa4609
In Vitro Model	MV4‐11	Childhood acute monocytic leukemia	Homo sapiens (Human)	CVCL_0064
	MOLM-13	Adult acute myeloid leukemia	Homo sapiens (Human)	CVCL_2119
In Vivo Model	MOLM13‐luciferase cells (1×10⁶) were injected into each mouse via the tail vein. After 6 days, cell engraftment was assessed after intraperitoneal injection of luciferin.
Result	ACC010 and HHT cooperatively downregulated MYC and inhibited FLT3 activation. Further, when HHT was added, ACC010-resistant cells demonstrated a good synergy. We also extended our study to the mouse BaF3 cell line with FLT3-inhibitor-resistant FLT3-ITD/tyrosine kinase domain mutations and AML cells without FLT3-ITD. Collectively, our results suggested that the combination treatment of ACC010 and HHT might be a promising strategy for AML patients, especially those carrying FLT3-ITD.